Cybin selects generalized anxiety disorder as target indication for deuterated dmt molecule cyb004

Toronto--( business wire )--cybin inc. (neo: cybn) (nyse american: cybn) (cybin or the company), a biotechnology company focused on progressing psychedelics to therapeutics® today announced that it has selected generalized anxiety disorder (“gad”) with or without major depressive disorder (“mdd”) as the target indication for its proprietary deuterated n, n-dimethyltryptamine (“dmt”) molecule, cyb004.
CYBN Ratings Summary
CYBN Quant Ranking